

iHEAD / IHA

(in association with the American Headache Society)

Vancouver, 4-5 September 2017

Programme

Monday 4 th September 2017				
12:00	Faculty & Delegate Reception & Lunch			
13:15	Welcome and Introductions			
13:30	Interactive clinical teaching cases			
	Chairs: Allan Purdy, Andrew Charles			
	Four cases, each by one delegate (20 min each: 10 min presentation + 10 min discussion)			
	Debate (two teams of three pro and three con delegates)			
	Chairs: Arne May, David Dodick			
	Background: Why classifications cannot be verified			
	That the ICHD-3-beta tension-type headache criteria are not fit for purpose			
15:00	Format 3 min: Chair's introduction of resolve and pre-debate voting 15 min: Pro Team (3 x 5 min) 15 min: Con Team (3 x 5 min) 10 min: Discussion with audience 1 min: Pro conclusion 1 min: Con conclusion 2 min: Chair: post-debate voting and conclusion			
15:45	Coffee break			

	Best clinical papers since June 2016
16:15	Chairs: Messoud Ashina, Patricia Pozo Rosich
	Seven papers, each by one delegate (12 min each: 7 min presentation + 5 min discussion)
17:45	
17.43	Headache science – how do I make a career?
	Phillip Holland and Amynah Pradhan
	Debate (two teams of three pro and three con delegates)
	Chairs: Arne May, Werner Becker
18:15	That migraine originates in the neck
	<u>Format as before</u>
19:30	Group Dinner

Tuesday 4 th September 2017						
08:00	Best basic science papers since June 2016 Chairs: Philip Holland, Amynah Pradhan Seven papers, each by one delegate (12 min each: 7 min presentation + 5 min discussion)					
09:30	Interactive Workshops					
	Presentation skills – oral Chairs: Messoud	Delegate poster presentations Chairs: Michel Ferrari,	Clinical case presentations Chairs: Werner	Reviewing papers - do's and don'ts		
	Ashina, Andrew Charles	Phillip Holland, Amynah Pradhan	Becker, Patricia Pozo Rosich	Arne May/David Dodick		
11:00	Coffee break					

	Debates (two teams of three pro and three con delegates for each debate)		
11.30	Migraine aura triggers migraine pain		
	Chairs: Messoud Ashina, Allan Purdy		
	That CGRP and CGRP receptor antibodies are likely no better than currently available treatments for most patients with migraine		
	Chairs: Michel Ferrari, Andrew Charles		
	Format as before		
13.00	Lunch and Adjourn		